I n experimental models of brain ischemia, matrix metalloproteinases (MMPs) have been shown consistently to play a detrimental role.
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Blood samples were taken before and 24 hours after tPA. Outcomes were defined as follows: (1) symptomatic intracerebral hemorrhage (SICH), using the National Institute of Neurological Disorders and Stroke criteria; 7 (2) 3-month death; (3) modified Rankin disability score, dichotomized into good (modified Rankin scale, 0-2) or poor (modified Rankin scale, 3-6) outcome. As a main explanatory variable, we used single patient's relative pre-and post-thrombolysis variation (Δ median value) of both MMPs and TIMPs levels, calculated according to the formula: (24-hour post-tPA MMP or TIMP-pre-tPA MMP or TIMP)/pre-tPA MMP or TIMP. Differences in these Δ values were analyzed in relation to demographic and clinical features and across subgroups of patients with different outcomes. Methods details are in the online-only Data Supplement.
Results
Between October 2008 and June 2011, 534 patients were registered in the SITS-ISTR, of whom 327 (mean age, 68.9±12.1 years; 58% males) were investigated. The remaining 207 were not studied because of not fulfilling SITS-MOST criteria, not giving consent, blood samples not taken or not stored appropriately, outcomes not assessed, and other protocol violations. Except for onset-to-treatment time, the prevalence of major outcomes determinants did not differ significantly between the 2 groups (demographics and clinical characteristics of both groups are in Table I in the online-only Data Supplement) .
Absolute TIMPs or MMPs measures taken before thrombolysis and 24 hours after are reported in the Table II in the  online-only Data Supplement. The Figure shows pre-and post-thrombolysis changes of each MMP and TIMP level measured in patients with and without SICH, in patients who died and in those who survived, and in patients scoring 3 to 6 or 0 to 2 on the 3-month modified Rankin scale. MMP9, TIMP4, and MMP2 level changes showed a tendency toward the association with SICH. Variations of MMP8, MMP9, and TIMP1 levels were significantly associated with death, whereas variations of MMP8, MMP9, and TIMP4 levels were associated with scoring 3 to 6 on the 3-month modified Rankin scale. Grading of hemorrhage severity (according to the European Cooperative Acute Stroke Study II criteria) in the 27 patients with SICH is shown in Table III in the online-only Data Supplement. The association of MMP9 level variation with hemorrhage remained significant (P=0.036) after excluding the patients with less severe transformation (hemorrhagic infarction type 1).
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MMP9 level changes were significantly correlated with prethrombolysis, 24-hour, and 7-day National Institutes of Health Stroke Scale score (Spearman P=0.012, 0.040, and <0.001, respectively).
A similar correlation was found for TIMP4 variations (Spearman P<0.001, <0.001, and 0.007, respectively). Adjusting for clinical determinants, among all MMPs and TIMPs examined, only MMP9 changes remained significantly associated with SICH, whereas only MMP9 and TIMP1 level changes remained associated with death (Table) .
Discussion
In the largest series hitherto investigated of tPA-treated patients with ischemic stroke, in whom a number of different MMPs and TIMPs were measured before and after thrombolysis, MMP9 circulating level variation proved associated, independent of major clinical determinants, with SICH or death. The unfavorable role of MMP9 was further supported by the correlation between MMP9 changes and National Institutes of Health Stroke Scale ratings before and after thrombolysis. Our findings are consistent with experimental data demonstrating the detrimental role of MMP9 in the processes aggravating tissue damage in tPA-treated cerebral ischemia. 1, 2 In the setting of human ischemic stroke treated with thrombolysis, previous smaller studies 8 have focused on the relationship between circulating MMPs level variations and either hemorrhagic transformation or clinical outcomes. The different timing of blood sampling limits comparisons across these studies.
One limitation of our study is the lack of a control group of patients with stroke not treated with tPA. A further limitation rests on methods used for measuring MMPs and TIMPs. Actually, we measured the antigen levels of MMPs and TIMPs, not their activities. Conversely, the zymographic assay procedure has poor standardization and high interlaboratory variability.
In conclusion, our study extends experimental data, suggesting a distinct role of MMP9 related to the course of ischemic stroke treated with thrombolysis, and may encourage randomized trials testing MMP9 antagonists administered together with tPA. 
Supplemental Material Supplemental Materials and Methods
Stroke severity was assessed using the Neurological Institute of Health Stroke Scale (NIHSS), administered before starting, at 24 hours and 7 days after thrombolysis; post-stroke disability and death by the modified Rankin Scale (mRS) administered at 3 months by visit or phone interview.
Patients had a non-contrasted head computed tomography (CT) scan at baseline and between 22 and 36 hours after treatment, and an additional CT scan in case of deterioration.
The outcome hemorrhagic transformation was assessed using NINDS criteria. 1 Hemorrhage grade was also rated using the European Cooperative Acute Stroke Study (ECASS II) criteria.
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Laboratory determinations
Blood was collected in tubes with anticoagulants (0.109 M sodium citrate at ratio 9:1 or 1.8 mg/mL EDTA), as well as in tubes without anticoagulant, before starting and 24 hours after thrombolysis.
Tubes were centrifuged at room temperature at 1500×g for 15 min, and the supernatants were stored in aliquots at −80°C until measurement of MMPs and TIMPs. Samples were analyzed in a unique central laboratory. Levels of different MMPs (MMP1, MMP2, MMP3, MMP7, MMP8, and MMP9) and TIMPs (TIMP1, TIMP2, and TIMP4) were determined using Bio-Plex suspension array system (Bio-Rad Laboratories Inc., Hercules, CA, USA) and R&D Kits (R&D System, Milan Italy) following manufacturer's instructions. The coefficient of variation of MMPs and TIMPs assays were 5.8% and 6.8%, respectively.
Statistical analysis
We 
